New Study Reveals Dark Side of Mounjaro: Weight Loss Jab Loses Its Effectiveness After Stopping Use
A recent study has shed light on a concerning trend associated with the popular weight-loss medication Mounjaro. Researchers found that individuals who discontinue using tirzepatide, an active ingredient in Mounjaro, not only regain weight but also experience a reversal of other health benefits they had achieved while taking the medication.
The study, which involved over 300 participants with obesity or overweight issues, revealed that within a year of stopping tirzepatide, nearly three-quarters of those who had lost at least 10% of their body weight initially regained 25% or more of what they had lost. The researchers also found that the extent of weight regain was correlated with the degree to which other health markers β such as blood pressure, waist circumference, and levels of "bad" cholesterol β reverted to baseline values.
Experts say this is not a surprising finding, given the well-established link between excess weight and elevated blood pressure, impaired glucose control, and other cardiometabolic risks. Dr. Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that when weight loss achieved through medication is regained, these risk factors tend to increase in proportion to the speed and extent of weight regain.
The study's findings have significant implications for the long-term management of obesity and related health conditions. While Mounjaro has shown promise in helping people lose an average of 20% of their body weight over 72 weeks, its effects are short-lived once use is discontinued. Dr. Jane Ogden, an emeritus professor at the University of Surrey, warned that relying on weight-loss medications without developing sustainable lifestyle habits can lead to a reversal of health benefits.
The study's authors emphasized the importance of long-term maintenance of weight reduction through a combination of lifestyle intervention and medication management to sustain cardiometabolic benefits and improved health-related quality of life.
A recent study has shed light on a concerning trend associated with the popular weight-loss medication Mounjaro. Researchers found that individuals who discontinue using tirzepatide, an active ingredient in Mounjaro, not only regain weight but also experience a reversal of other health benefits they had achieved while taking the medication.
The study, which involved over 300 participants with obesity or overweight issues, revealed that within a year of stopping tirzepatide, nearly three-quarters of those who had lost at least 10% of their body weight initially regained 25% or more of what they had lost. The researchers also found that the extent of weight regain was correlated with the degree to which other health markers β such as blood pressure, waist circumference, and levels of "bad" cholesterol β reverted to baseline values.
Experts say this is not a surprising finding, given the well-established link between excess weight and elevated blood pressure, impaired glucose control, and other cardiometabolic risks. Dr. Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that when weight loss achieved through medication is regained, these risk factors tend to increase in proportion to the speed and extent of weight regain.
The study's findings have significant implications for the long-term management of obesity and related health conditions. While Mounjaro has shown promise in helping people lose an average of 20% of their body weight over 72 weeks, its effects are short-lived once use is discontinued. Dr. Jane Ogden, an emeritus professor at the University of Surrey, warned that relying on weight-loss medications without developing sustainable lifestyle habits can lead to a reversal of health benefits.
The study's authors emphasized the importance of long-term maintenance of weight reduction through a combination of lifestyle intervention and medication management to sustain cardiometabolic benefits and improved health-related quality of life.